Stock data
Immunic, Inc. (IMUX)
Immunic, Inc. (IMUX) reported net income of -US$97.17M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$103.23M | -US$97.17M | — |
| 2024 | — | — | -US$98.05M | -US$100.51M | — |
| 2023 | — | — | -US$99.22M | -US$93.61M | — |
| 2022 | — | — | -US$119.49M | -US$120.41M | — |
| 2021 | — | — | -US$91.67M | -US$92.94M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$34.10M | — |
| 2026-03-31 | — | -US$32.59M | — |
| 2025-12-31 | — | -US$19.30M | — |
| 2025-09-30 | — | -US$25.58M | — |
| 2025-06-30 | — | -US$26.82M | — |
| 2025-03-31 | — | -US$25.47M | — |
| 2024-12-31 | — | -US$25.18M | — |
| 2024-09-30 | — | -US$24.37M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.